Search Blog
August 2018
« Jul   Sep »


Biotech and Cannabis Companies Set to Own The Future


By ACR Communication, LLC

HENDERSON, NV / ACCESSWIRE / August 8, 2018 / With investors piling into biotechnology, and cannabis stocks the future is upon us. Intelligent investors see the writing on the wall. Biotechnology, and cannabis based firms are here to stay, and this is just the beginning of a run that could last decades in both sectors.

We will be discussing several companies that could be in for an incredible future. Two industries that have strongly caught our attention include Stem Cell Therapies, and Cannabinoid based Biotechnology. BRTX is a stem cell firm that has been receiving major attention from the street as of late. If you are discovering BRTX for the first time we suggest you start conducting your own research on BRTX immediately. BRTX is currently preparing for a phase 2 clinical trial for its product BRTX-100. Investors that discover BRTX before the company starts its Phase 2 clinical trial could be in for a massive discovery.

Now let’s take a close look at BRTX, and other companies that will own the future.

BioRestorative Therapies, Inc. (BRTX)

Market Cap: $10.57M Share Price: $2.80

BioRestorative Therapies, Inc. (BRTX), a life sciences company focused on stem cell-based therapies, recently announced the appointment of Jason S. Lipetz, M.D. to the Company’s Scientific Advisory Board. Dr. Lipetz has an impressive resume and will certainly add clinical expertise as the Company prepares for its Phase 2 trial using BRTX-100 to treat chronic lumbar disc disease. The stock is up big over the last week and, announcements like these many times lead to more positive news in the near future. Investors should closely monitor this situation.

Cara Therapeutics, Inc. (NASDAQ: CARA)

Market Cap: $738.4M, current share price: $18.91

Cara Therapeutics, Inc. (CARA), a U.S. biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, announced that it has licensed worldwide rights, except in the U.S., Japan and South Korea, to commercialize KORSUVA (CR845/difelikefalin) injection for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in dialysis patients to Vifor Fresenius Medical Care Renal Pharma Ltd (VFMCRP), a joint company of Vifor Pharma Group (VIFN.VX) and Fresenius Medical Care (FMS) that specializes in treatments for CKD. The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to KORSUVA injection for this indication, for which there are currently no approved therapies in the U.S. or E.U.

Insys Therapeutics, Inc. (INSY)

Market Cap: $575.0M Share Price: $7.30

Not all CBD companies have had positive news, a couple weeks ago, Insys Therapeutics, Inc announced the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns. Insys’ treatment is an under-the-tongue spray formulation of the opioid buprenorphine that was under review to treat moderate-to-severe pain. Despite the negative news, the stock is trading up today, and could be heading for its 52W High.

Zynerba Pharmaceuticals Inc. (ZYNE)

Market Cap: $115.8M, current share price: $6.57

Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) is a clinical-stage specialty neuropsychiatric pharmaceutical company dedicated to developing and commercializing innovative pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric diseases with high unmet medical needs. ZYNE is down big this year, and could see a strong correction to the upside at anytime now.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. ACR Communication, LLC, which owns, is not registered with Finra or any other financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. ACR Communication, LLC [and/or] does not have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. ACR Communication LLC, which owns, is compensated for its services in the form of cash-based compensation or in equity in the companies it writes about, or a combination of the two. ACR Communication, LLC has been compensated one thousand dollars cash for this article and eleven thousand dollars total by Regal Consulting. LLC, for news commentary articles for BRTX. BRTX and Regal Consulting, LLC were given an opportunity to edit information included in this article. This article is based solely on public information and the opinions of ACR Communication, LLC, which believes the news commentary to include accurate and complete information. ACR Communication, LLC, will not buy or sell any shares in stocks contained within this article for forty eight hours after this article’s distribution.

For Full Legal Disclaimer Click Here.

Contact Information:

Company Name: Microcap Speculators
Contact Person: Media Manager
Phone: 1-702-720-6310
Country: United States

SOURCE: ACR Communication, LLC

ReleaseID: 509329